Leading the way to safer medication
 Crosscheck  Recommender


Brand names: FASENRA

Therapeutic Indications

Benralizumab is indicated for:

Severe eosinophilic asthma

Irrespective of gender only Adults (18 years old or older)

Benralizumab is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Subcutaneous - 30 mg once every 4 weeks


Active ingredient Benralizumab is contraindicated in the following cases: